Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.
Authors: Williams L B, Koenig J B, Black B, Gibson T W G, Sharif S, Koch T G
Journal: Equine veterinary journal
Summary
# Editorial Summary Williams and colleagues investigated the immunomodulatory potential of allogeneic umbilical cord blood-derived mesenchymal stromal cells (CB-MSCs) in a controlled lipopolysaccharide (LPS) model of equine joint inflammation, addressing a significant gap in understanding the mechanisms underlying clinical improvements reported after intra-articular MSC therapy. Their randomised, blinded experimental design induced synovitis in middle carpal joints bilaterally with LPS before injecting 30 million CB-MSCs into one joint, tracking lameness, synovial fluid analysis and biomarkers over 72 hours. The principal finding was that CB-MSC injection significantly reduced synovial fluid nucleated cell counts (total neutrophils and mononuclear cells) in LPS-inflamed joints compared with untreated contralateral controls, though no differences emerged in other synovial fluid parameters or biomarkers; notably, CB-MSC injection alone induced mild, self-limiting synovitis that resolved without intervention, with transient lameness in two horses and severe lameness (grade 4) in one at 24 hours. For practitioners considering intra-articular MSC therapy, these results suggest a genuine anti-inflammatory effect on established joint inflammation, but also highlight that MSC injection carries inherent inflammatory consequences requiring careful patient selection and monitoring—the authors emphasise that optimal dosing, timing relative to injury or inflammation onset, and treatment frequency remain critical unknowns requiring further investigation.
Read the full abstract on PubMed
Practical Takeaways
- •Allogeneic CB-MSC therapy shows promise for reducing inflammatory cell populations in joint synovitis, though clinical lameness improvement is not guaranteed
- •Single 30-million cell CB-MSC injections induce only mild, self-resolving inflammation, suggesting reasonable safety profile for intra-articular use
- •Current evidence is preliminary (n=3); practitioners should await larger studies on optimal dosing, timing, and treatment frequency before adopting CB-MSC therapy as standard practice
Key Findings
- •Allogeneic umbilical cord blood-derived mesenchymal stromal cells (CB-MSCs) reduced synovial fluid total nucleated, neutrophil, and mononuclear cell numbers compared to LPS-only joints
- •CB-MSC injection alone induced mild self-limiting synovitis that resolved without treatment
- •Mild to severe lameness occurred in CB-MSC-treated limbs at 24 hours post-injection but did not correlate with synovitis severity
- •No significant differences were detected in other synovial fluid parameters or biomarkers between CB-MSC-treated and LPS-only joints